Jump to:
Alyce Chen advises multinational companies in the life sciences, technology and other sectors on a range of strategic transactions, including cross-border mergers, acquisitions, joint ventures and equity financings. Alyce also advises clients on corporate governance, disclosure issues and compliance matters.
Experience
- Advised numerous life sciences and consumer goods companies in venture financing transactions from formation to exit and on corporate governance, intellectual property, and other ongoing commercial matters.
- Advised public companies in the life sciences and technology sectors on public company and securities compliance, including on Nasdaq and Hong Kong Stock Exchange compliance matters.
- Represented various venture capital firms investing in companies in the life sciences and consumer goods sectors in the U.S. and the Asia-Pacific region.
- Represented various multinational companies, including Johnson & Johnson and Fibrogen, in mergers, acquisitions, joint ventures and divestitures in the Asia-Pacific region.
- Represented Everest Medicines in a US$455 million agreement with Immunomedics, Inc., a wholly-owned subsidiary of Gilead Sciences, in obtaining exclusive rights to develop and commercialize cancer drug Trodelvy in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia.
- Represented Perceptive Advisors, TPG, Bain and JJDC (venture arm of Johnson & Johnson), among others, in their other respective investments and strategic transactions in China and the Asia Pacific region.